Loading
Review on JAK2 in Polycythaemia vera, in Nature Reviews Cancer (2007), one of the most cited Europe PMC records with JAK2 in its title.
The myeloproliferative disorders polycythaemia vera (PV), essential thombocythaemia (ET), and primary myelofibrosis (PMF) are clonal disorders of multipotent haematopoietic progenitors. The genetic cause of these diseases was not known until 2005, when several independent groups demonstrated that most patients with PV, ET and PMF acquire a single point mutation in the cytoplasmic tyrosine kinase JAK2 (JAK2V617F). These discoveries have changed the landscape for diagnosis and classification of PV, ET and PMF, and show the ability of genomic technologies to identify new molecular targets in human malignancies with pathogenetic, diagnostic and therapeutic significance.
Indexed on Europe PMC as PubMed record 17721432 (DOI 10.1038/nrc2210). Its title names JAK2 and its text names Polycythaemia vera; PubMed types it as a review (Research Support, Non-U.S. Gov't, Review, Research Support, N.I.H., Extramural). It was matched automatically to the idea "Clearing the JAK2 clone in polycythaemia vera: interferon plus mutant-selective inhibitors as a route to treatment-free remission" and no figure has been checked by an editor.
One of the most cited reviews Europe PMC returns for JAK2 in Polycythaemia vera, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.